Comparison of Low-dose Spiral Breast CT with MRI in Major Indications of MRI for Breast Diagnostics

Last updated: January 28, 2025
Sponsor: AB-CT - Advanced Breast-CT GmbH
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Injection of contrast enhancing agent Imeron for B-CT investigation

Injection of contrast enhancing agent Gadovist for MRI investigation

Clinical Study ID

NCT05989022
ldBCT-MRI-C
  • Ages > 18
  • Female
  • Accepts Healthy Volunteers

Study Summary

Comparison between two diagnostic modalities for breast cancer diagnosis. Two different imaging systems are compared to evaluate the performance of the two systems

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Sex: female

  2. Age: at least 18 years

  3. Inconclusive findings in conventional imaging or preoperative staging or evaluationof therapy response in the neoadjuvant chemotherapy setting or imaging of the breastafter breast-conserving therapy or finding the cause of hemorrhagic nipple dischargeor prosthesis imaging or screening of women with hereditary or familial increasedrisk for the development of breast cancer or axillary lymph node metastasissuspected to originate from breast tissue

  4. Persons able and willing to understand and sign informed consent form

Exclusion

Exclusion Criteria:

  1. Known pregnancy or breastfeeding

  2. Presence of BRCA1 or BRCA2 allele

  3. Insufficient renal function (MDRD)

  4. Dysfunction of the thyroid gland (TSH degradation)

  5. Known allergy or intolerance against iodine-containing contrast enhancing agents orMRI contrast enhancing agents

  6. Patients with paramagnetic or magnetic material inside the breast, claustrophobia

Study Design

Total Participants: 428
Treatment Group(s): 2
Primary Treatment: Injection of contrast enhancing agent Imeron for B-CT investigation
Phase:
Study Start date:
November 24, 2023
Estimated Completion Date:
December 31, 2025

Study Description

The diagnostic quality of MRI of the breast has made this method a gold standard in the imaging of senologic lesions. Low-dose dedicated breast CT (BCT) with single photon-detection (nu:view, developed by AB-CT - Advanced Breast-CT GmbH) has emerged as a fully 3D imaging modality that uses ionizing radiation comparable to 2D mammography and has its intended use in helping with diagnosis in diagnostic breast imaging.

The investigation is designed as a prospective non-randomized intra-individual cohort procedure comparison between the imaging platforms, nu:view and MRI. Across 3 hospital-based study sites in two countries, study participants (patients who meet study criteria and have consented) sequentially receive nu:view imaging and, with a delay of up to one week (preferably on the same day), MRI imaging. At both times, patients receive contrast agent. Images generated from breasts are evaluated by three independent radiologists and their scores and interpretations are statistically evaluated. The research aim is to demonstrate non-inferiority of BCT compared with MRI in major indications of MRI for breast diagnostics.

The perceived gain in the study is to generate data on clinical performance of the BCT device nu:view and on the procedure that could be supportive of a tailored use of nu:view in patients with major indications of MRI for breast diagnostics.

Connect with a study center

  • DRZ Die Radiologen

    Regensburg, Bavaria 93059
    Germany

    Active - Recruiting

  • Radiologisches Institut Universitätsklinikum Erlangen

    Erlangen, 91054
    Germany

    Active - Recruiting

  • Stichting Martini Ziekenhuis

    Groningen, 9728 NT
    Netherlands

    Active - Recruiting

  • Leiden University Medical Centre

    Leiden, 2333 ZA
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.